|
Rate of occult metastases in patients (pts) with biochemically-recurrent prostate cancer (BRPC) from a phase 2 trial of sipuleucel-T and androgen deprivation therapy (STAND). |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc. |
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc. |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst) |
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst) |
|
|
Consulting or Advisory Role - Agensys; AstraZeneca; Bayer; Dendreon; EMD Serono; Ferring; Genentech/Roche; Janssen; Lilly; Medivation; Merck; Tokai Pharmaceuticals |
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); GTx (Inst); Lilly/ImClone (Inst); Merck (Inst) |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Dendreon; Endocyte; Janssen Oncology; Mannkind; Pfizer; UpToDate |
Consulting or Advisory Role - Amgen; AVEO; Bayer; BIND Biosciences; Cerulean Pharma; Churchill Pharmaceuticals; Genentech/Roche; HERON; Janssen Biotech; Labceutics; Pfizer |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi |
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Swan Valley Medical |
Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas |
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Medivation |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Janssen (Inst); Medivation/Astellas (Inst); Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; dendreon; Janssen; Medivation/Astellas; Spectrum Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Dendreon; Ferring; Janssen Scientific Affairs; Medivation/Astellas; Sanofi; Takeda; Tolmar |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Dendreon |
|
|
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi |
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi |